Menu Search
Equities

Verona Pharma PLC

I9SA:HAM

Verona Pharma PLC

Actions
  • Price (EUR)11.60
  • Today's Change0.300 / 2.65%
  • Shares traded-1.00
  • 1 Year change-40.21%
  • Beta--
Data delayed at least 15 minutes, as of May 23 2024 07:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

  • Revenue in USD (TTM)0.00
  • Net income in USD-63.42m
  • Incorporated2005
  • Employees79.00
  • Location
    Verona Pharma PLCRiverside, 3 More London PlaceLONDON SE1 2REUnited KingdomGBR
  • Phone+44 203 283 4200
  • Fax+44 207 863 3314
  • Websitehttps://www.veronapharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.